Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACB | P22694 | 1/20 | 0.57 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.54 |
| ▸ | NMBR | P28336 | 2/20 | 0.51 |
| ▸ | GHSR | Q92847 | 3/20 | 0.50 |
| ▸ | BMP1 | P13497 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511199 | 0.94 | NPBWR1 (0.57) | PRKACBNPBWR1GHSR | |
| SCHEMBL30866237 | 0.93 | NPBWR1 (0.55) | PRKACBNPBWR1NMBRGHSRC5AR1 | |
| SCHEMBL29641046 | 0.93 | GHSR (0.56) | PRKACBNMBRGHSRNPY2R | |
| SCHEMBL30990571 | 0.93 | GHSR (0.56) | PRKACBNMBRGHSRNPY2R | |
| SCHEMBL29511112 | 0.93 | GHSR (0.56) | PRKACBNMBRGHSRNPY2R | |
| SCHEMBL29790169 | 0.92 | GHSR (0.56) | PRKACBNPBWR1NMBRGHSRNPY2R | |
| SCHEMBL29484173 | 0.92 | GHSR (0.56) | PRKACBNPBWR1NMBRGHSRNPY2R | |
| SCHEMBL29609768 | 0.92 | GHSR (0.56) | PRKACBNPBWR1NMBRGHSRNPY2R | |
| SCHEMBL31593359 | 0.92 | GHSR (0.56) | PRKACBNPBWR1NMBRGHSRNPY2R | |
| SCHEMBL29790108 | 0.92 | GHSR (0.56) | PRKACBNPBWR1NMBRGHSRNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| CN-119119190-A | Melanocortin receptor ligands | 益普生制药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | PRKACB 1262/4885NPBWR1 29/4885NMBR 204/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | PRKACB 1401/4885NPBWR1 45/4885NMBR 138/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | PRKACB 2607/4885NPBWR1 51/4885NMBR 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.